WallStSmart
CASI

CASI Pharmaceuticals Inc

NASDAQ: CASI · HEALTHCARE · BIOTECHNOLOGY

$0.21
+0.00% today

Updated 2026-04-29

Market cap
$3.21M
P/E ratio
P/S ratio
0.12x
EPS (TTM)
$-3.02
Dividend yield
52W range
$0 – $3
Volume
1.0M

CASI Pharmaceuticals Inc (CASI) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
-36.5%
Last 4 quarters
Revenue YoY growth
-60.5%
Most recent quarter
EPS YoY growth
-23.6%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-10.9%
Last 1 reports
Positive reaction rate
0%
0 of 1 quarters
Largest single-day move
-10.9%
2025-11-14
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2025-11-14$-0.68-13.3%$1.34$1.19-10.9%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-09-30$-0.60$-0.68-13.3%$3.08M-60.5%
2025-06-30$-0.47$-0.86-83.0%$4.17M+4.9%
2025-03-31$-0.61$-0.69-13.1%$6.24M+83.0%
2024-12-31$0.03$-0.75-2600.0%$13.36M+94.3%
2024-09-30$-0.62$-0.55+11.3%$7.79M-11.8%
2024-06-30$-0.63$-0.55+12.7%$3.98M-59.5%
2024-03-31$-0.05$-0.71-1320.0%$3.41M-59.2%
2023-12-31$-0.24$-0.45-87.5%$6.87M-55.0%
2023-09-30$-0.56$-0.35+37.5%$8.84M
2023-06-30$-0.50$-0.77-54.0%$9.82M
2023-03-31$-0.64$-0.45+29.7%$8.35M
2022-12-31$-0.37$-1.44-289.2%$15.26M

Frequently asked questions

Has CASI Pharmaceuticals Inc beaten earnings estimates?
CASI Pharmaceuticals Inc has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of -36.5% over the last 3 quarters.
How does CASI stock react to earnings?
CASI stock has moved an average of -10.9% in the trading day following earnings over its last 1 reports, with positive reactions in 0% of those quarters.
What is CASI Pharmaceuticals Inc's revenue growth rate?
CASI Pharmaceuticals Inc reported year-over-year revenue growth of -60.5% in its most recent quarter, with EPS growing -23.6% year-over-year.